CI vs NBIX · P/E 2.4, rev $274.90B vs P/E 45, rev $2.36B
Cigna Corp (CI) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
Cigna Corp (CI) is a healthcare plans company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported CI revenue for 2025-12-31 was $274.90B. Net income was $5.96B. Revenue was up 11.2% from 2024-12-31 to 2025-12-31. CI currently screens at market cap $71.62B and trailing P/E 2.4.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
CI currently screens at market cap $71.62B and trailing P/E 2.4. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the CI and NBIX stock pages for the full models.
Not investment advice.